SARS-CoV-2 RBD nanoparticle vaccine shows potent neutralization against variants in clinical studies
Summary
This article describes the characterization of a two-component protein nanoparticle vaccine platform (RBD-NP) that displays 60 copies of the SARS-CoV-2 spike protein RBD. The vaccine, adjuvanted with AS03 and branded as SKYCovione™, has shown robust neutralizing antibody and CD4 T cell responses in clinical trials, met primary endpoints in Phase III, and received regulatory licensure. The paper details the biophysical properties, stability, and neutralizing activity of the immunogens against SARS-CoV-2 variants.
Source
Twitter / XSARS-CoV-2 RBD nanoparticle vaccine shows potent neutralization against variants in clinical studiespmc.ncbi.nlm.nih.govKey quotes
· 3 pulledWe previously described a two-component protein nanoparticle vaccine platform that displays 60 copies of the SARS-CoV-2 spike protein RBD (RBD-NP).
The vaccine, when adjuvanted with AS03, was shown to elicit robust neutralizing antibody and CD4 T cell responses in Phase I/II clinical trials.
The vaccine met its primary co-endpoints in a Phase III trial, and has been licensed by multiple regulatory authorities under the brand name SKYCovioneTM.
You might also wanna read
Nanoliposome-based subunit vaccine platform targets multiple respiratory viruses simultaneously
This article describes a novel nanoliposome-based subunit vaccine platform designed to simultaneously target multiple respiratory viruses, i
science.org·4d ago
Phase I trial shows needle-free pan-Sarbecovirus vaccine is safe with modest immune responses
This article reports on a first-in-human Phase I clinical trial of pEVAC-PS, a computationally designed pan-Sarbecovirus vaccine delivered v
Correspondence: Nirmatrelvir–ritonavir suppresses viral load but may attenuate spike antibody response
This correspondence article discusses findings from the PANORAMIC trial published in The Lancet Microbe, showing that nirmatrelvir–ritonavir
Moderna's combined flu and COVID-19 mRNA vaccine shows durable immune response in mid-stage trial
Moderna announced promising results from a mid-stage trial of its combined mRNA seasonal flu and COVID-19 vaccine (mRNA-1073). The study inv
cidrap.umn.edu·18d ago
mRNA-LNP Platforms Show Promise for Inducing Immune Tolerance in Peanut Allergy Treatment
This article discusses the development of mRNA-lipid nanoparticle (LNP) platforms designed to induce antigen-specific immune tolerance for p
pubs.acs.org·22d ago
AI-designed universal coronavirus vaccine shows safety and immune response in first human trial
An AI-designed universal coronavirus vaccine developed by the University of Cambridge and DIOSynVax has successfully passed its first human
Comments
Sign in to join the conversation.
No comments yet. Be the first.